PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)
Status:
Completed
Trial end date:
2018-10-03
Target enrollment:
Participant gender:
Summary
This study is an open-label,non randomized, multi-center, phase 1/2b (dose escalation
followed by expansion part) study evaluating clinical safety, efficacy and pharmacokinetics
of PQR309 in combination with standard dose of eribulin in patients with locally advanced or
metastatic HER2-negative (escalation part) and Triple Negative Breast Cancer (expansion
part).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
PIQUR Therapeutics AG
Collaborators:
Barts Cancer Institute Churchill Hospital Fundación Instituto Valenciano de Oncología Hospital Universitari Vall d'Hebron Research Institute Hospital Universitario Ramon y Cajal Institut Català d'Oncologia